Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology.
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, ManchesterIssue Date
2016-09
Metadata
Show full item recordAbstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer-related death. The high rate of diagnosis in non-curable stages and the lack of novel active treatments make it necessary to review all the possible sources of misleading results in this scenario. The incidence of HCC shows clear geographical variation with higher annual incidence in Asia and Africa than in Western countries; we aimed to review the literature to find if there are different trends in the main activated molecular pathways. Hyperactivation of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signalling and epithelial to mesenchymal transition (EMT) process are more prevalent in the Western population; however, fibroblast growth factor (FGF), transforming growth factor β (TGFβ) and Notch pathways seems to be more relevant in Asian population. Whether these variations just reflect the distinct distribution of known causes of HCC or proper ethnical differences remain to be elucidated. Nevertheless, these clearly different patterns are relevant to regional or worldwide clinical trial design. If this information is neglected by sponsors and researchers the rate of failure in HCC trials will not improve.Citation
Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. 2016, 105:65-72 Crit. Rev. Oncol. Hematol.Journal
Critical Reviews in Oncology/HematologyDOI
10.1016/j.critrevonc.2016.06.007PubMed ID
27372199Type
ArticleLanguage
enISSN
1879-0461ae974a485f413a2113503eed53cd6c53
10.1016/j.critrevonc.2016.06.007
Scopus Count
Collections
Related articles
- Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
- Authors: Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ
- Issue date: 2016 Jun 14
- From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
- Authors: Pang RW, Poon RT
- Issue date: 2007
- Targeted therapy of hepatocellular cancer.
- Authors: Wysocki PJ
- Issue date: 2010 Feb
- PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
- Authors: Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM
- Issue date: 2012 Aug
- [Expression of Nodal in hepatocellular carcinoma and its relationship with angiogenesis and epithelial-mesenchymal transition].
- Authors: Chen J, Li J, Liu W, Jia W, Xu G, Ma J
- Issue date: 2014 Mar